Drug to Treat Alzheimer’s Proves Dangerous
July 25, 2013
What scientists had hoped to be a promising new drug in the treatment of Alzheimer’s disease proved dangerous in its final phase of testing. The trial randomized 1,537 men and women with probable Alzheimer’s disease into three groups of recipients: placebo, 100 milligrams of semagacestat, or 140 milligrams of semagacestat. Changes in cognition and functioning worsened for all three groups with the worst scores seen in the groups that received the experimental drug. Patients treated with semagacestat lost more weight and had more skin cancers, infections, and gastrointestinal problems, compared with those who received the placebo. The trial was terminated early due to safety concerns.
To date, the safest and most promising hope for Alzheimer’s disease is prevention through lifestyle changes. Read the Physicians Committee’s Dietary Guidelines for Alzheimer’s Prevention here.
Doody RS, Rama R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369:341-350.
Subscribe to PCRM's Breaking Medical News.
Breaking Medical News is a service of the Physicians Committee for Responsible Medicine, 5100 Wisconsin Ave., Ste. 400, Washington, DC 20016, 202-686-2210. Join PCRM and receive the quarterly magazine, Good Medicine.